
ALT A dental treatment can stop cavities without drilling or injections. Scientists are studying a simple liquid called silver diamine fluoride (SDF) that can stop tooth decay without the need for conventional drilling or anesthesia. The treatment is applied directly to a cavity with a small brush and takes only seconds. A 2025 randomized clinical trial involving 665 children found that approximately 80% of treated cavities became inactive after a brief application. How does it work? Silver helps kill cavity-causing bacteria, while fluoride strengthens weakened tooth structure and helps prevent further decay. Another major U.S. clinical trial found that 54% of cavities treated with SDF stopped progressing, compared with 21% in the placebo group. This approach could be particularly helpful for young children who find traditional dental procedures difficult.

ALT WHAT IF YOUR BODY COULD GROW A NEW TOOTH AFTER LOSING ONE? Imagine replacing missing teeth without implants, dentures or artificial replacements. Japanese scientists are investigating a treatment that could one day make this possible. The secret lies in a protein called USAG-1, which normally acts as a brake on tooth development. Researchers developed an experimental antibody called TRG035 to block this protein and potentially activate the growth of new teeth. In animal studies involving mice and ferrets, the treatment produced encouraging results, including the development of new teeth. Human testing began in Japan in 2024. The first clinical trial has now been completed, primarily to assess safety. However, scientists have not yet demonstrated that the treatment can regrow missing teeth in humans. It is still experimental, but the possibility of naturally growing replacement teeth could transform the future of dentistry.

ALT **A Pancreatic Cancer Vaccine Activated the Immune System in 89 Out of 90 Patients** What if a vaccine could teach the immune system to recognize one of the deadliest cancers? Researchers tested an experimental vaccine called ELI-002 7P in 144 patients with pancreatic cancer who had already undergone surgery and treatment. The vaccine targets seven common KRAS mutations that help cancer cells survive. The results were remarkable: **89 out of 90 evaluable vaccinated patients developed stronger T-cell responses** against these cancer-related mutations. These immune cells are responsible for recognizing and attacking abnormal cells. But there is an important twist. Despite the powerful immune response, the Phase 2 trial did not meet its main goal of significantly delaying cancer recurrence across all participants. Researchers are now investigating which patients may benefit most.

ALT 🧬 **A New Pancreatic Cancer Vaccine Activated the Immune System in Nearly 99% of Patients** What if the immune system could be trained to recognize one of the deadliest cancers? Scientists have developed an experimental vaccine called **camupepimut** that teaches immune cells to recognize specific genetic mutations linked to pancreatic cancer. In a phase 2 clinical trial involving 144 patients, the results caught researchers' attention. Among 90 vaccinated patients whose immune responses could be measured, **89 (98.9%) developed stronger T-cell responses** against cancer-related KRAS mutations. These immune cells are important because they can recognize and attack abnormal cells. Researchers also observed that patients with stronger immune responses tended to remain cancer-free for longer. But there is an important detail: the vaccine has not yet been proven to prevent cancer from returning or extend survival.























